Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Inhibrx (United States)
h-index: 9
Total citations: 214
Total papers: 40
Homepage:
https://inhibrx.com
Recent papers from Inhibrx (United States)
Delineating a reference interval for functional alpha-1 antitrypsin in the serum of healthy Pi*MM donors using an anti-neutrophil elastase capacity assay
Respiratory Research · 2026
The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.
Journal of Clinical Oncology · 2026
Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).
Journal of Clinical Oncology · 2026
B78-14 Establishing a Reference Interval for Functional Alpha-1 Antitrypsin in the Serum of Healthy Pi*MM Donors Using an Anti-neutrophil Elastase Capacity Assay
American Journal of Respiratory and Critical Care Medicine · 2026
Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial
Clinical Cancer Research · 2026
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
Journal for ImmunoTherapy of Cancer · 2025
Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study.
Journal of Clinical Oncology · 2025
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Journal of Clinical Oncology · 2024
Abstract 1081: A role for the oncogenic driver fusion protein EWS-FLI1 in the targeting of DR5 by INBRX-109 in Ewing sarcoma
Cancer Research · 2024
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing
Journal of Clinical Investigation · 2024
Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study
Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2024
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Clinical Cancer Research · 2023
Fully integrated downstream process to enable next‐generation manufacturing
Biotechnology and Bioengineering · 2023
INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses
Journal for ImmunoTherapy of Cancer · 2023
Selective inhibition of matrix metalloproteinase 10 (MMP10) with a single-domain antibody
Journal of Biological Chemistry · 2020
Long‐Term Dynamics in “Trophy” Sizes of Pelagic and Coastal Pelagic Fishes among California Recreational Fisheries (1966–2013)
Transactions of the American Fisheries Society · 2016
Open-Label, Dose Escalation Study of the Safety and Pharmacokinetic Profile of Tefibazumab in Healthy Volunteers
Antimicrobial Agents and Chemotherapy · 2005
Inhibition of Complement Activation by a SecretedStaphylococcus aureusProtein
The Journal of Infectious Diseases · 2004